EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study

Marco Contoli, Celeste Porsbjerg, Sarah Buchs, Julie Rask Larsen, Nick Freemantle, Benedikt Fritzsching

Journal of Allergy and Clinical Immunology · 2023-08 · 152 (2) · 445-452.e4

DOI: 10.1016/j.jaci.2023.02.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-08. Verfasst von Marco Contoli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Section, the Department of Translational Medicine, University of Ferrara, Ferrara, Italy. Electronic address: ctm@unife.it. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Sublingual Immunotherapy, Anaphylaxis, Dust Mite Allergy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Randomized controlled trials have demonstrated the efficacy of allergy immunotherapy (AIT) in allergic rhinitis (AR) and the disease-modifying effects of the SQ grass sublingual immunotherapy (SLIT) tablet. OBJECTIVE: We sought to assess real-world, long-term effectiveness and safety across AIT subgroups: route of administration, therapeutic allergen, persistence to AIT, and SQ grass SLIT tablet. METHODS: The primary outcome of AR prescriptions from a retrospective cohort study (REAl-world effeCtiveness in allergy immunoTherapy; 2007-2017) was assessed across prespecified AIT subgroups in subjects with AR with and without AIT prescriptions (controls). Safety was assessed as anaphylaxis for 2 days or less of the first AIT prescription. Subgroup follow-up continued until samples were fewer than 200 subjects. RESULTS: Subcutaneous immunotherapy (SCIT) and SLIT tablets showed similarly greater reductions in AR prescriptions than controls (SCIT vs SLIT tablets: year 3, P = .15; year 5, P = .43). Comparably greater reductions in AR prescriptions were observed for grass- and house dust mite-specific AIT than for controls, but significantly smaller reductions were observed for tree-specific AIT (tree vs house dust mite, and vs grass: years 3 and 5, P < .0001). Persistence to AIT was associated with greater reductions in AR prescriptions versus nonpersistence (persistence vs nonpersistence: year 3, P = .09; year 5, P = .006). SQ grass SLIT tablet showed sustained reductions versus controls for up to 7 years (year 3, P = .002; year 5, P = .03). Rates of anaphylactic shock were low (0.000%-0.092%), with no events for SQ SLIT tablets. CONCLUSIONS: These results demonstrate real-world, long-term effectiveness of AIT, complement disease-modifying effects observed in SQ grass SLIT-tablet randomized controlled trials, and highlight the importance of using newer evidence-based AIT products for tree pollen AR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhinitis, AllergicSublingual ImmunotherapyAnaphylaxisDust Mite AllergyAnimalsHumansRetrospective StudiesAllergensPoaceaeTabletsTreatment Outcome

Stichwörter der Autor:innen

Allergic rhinitisREACTSQ SLIT tabletallergy immunotherapycohort studyeffectivenessreal-world evidenceretrospectivesublingual immunotherapy

Substanzen

AllergensTablets

Autor:innen und Institutionen

  • Respiratory Section, the Department of Translational Medicine, University of Ferrara, Ferrara, Italy. Electronic address: ctm@unife.it.
  • Department of Respiratory Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Global Market Access, ALK-Abelló, Hørsholm, Denmark.
  • Global Medical Affairs, ALK-Abelló, Hørsholm, Denmark.
  • Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
  • Paediatric Pulmonology and Allergy, Children's Doctor Service, Heidelberg, Germany.

Zitieren

APA

Contoli, M., Porsbjerg, C., Buchs, S., Larsen, J. R., Freemantle, N., & Fritzsching, B. (2023). Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study. Journal of Allergy and Clinical Immunology, 152(2), 445-452.e4. https://doi.org/10.1016/j.jaci.2023.02.024

Vancouver

Contoli M, Porsbjerg C, Buchs S, Larsen JR, Freemantle N, Fritzsching B. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study. Journal of Allergy and Clinical Immunology. 2023;152(2):445-452.e4. doi:10.1016/j.jaci.2023.02.024

BibTeX
@article{Contoli2023,
  author = {Contoli, Marco and Porsbjerg, Celeste and Buchs, Sarah and Larsen, Julie Rask and Freemantle, Nick and Fritzsching, Benedikt},
  title = {Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {2},
  pages = {445--452.e4},
  doi = {10.1016/j.jaci.2023.02.024}
}
Kostenlos starten →